Prescription Medicines
Seleca Tab. 200mg
- Product Category
- Arthritis treatment
- Active Ingredients
- Celecoxib
- Appearance
- A white, oblong, film-coated tablet.
- Reimbursement Code
- 648103540
01 / 02
1. Composition and Strength
- Active ingredient: Celecoxib (EP)----200mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: sodium lauryl sulfate, titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, croscarmellose sodium, povidone, polyethylene glycol 6000, hypromellose
2. Effectiveness
1. Alleviation of symptoms and signs of osteoarthritis (degenerative arthritis)
2. Relief of symptoms and signs of rheumatoid arthritis
3. Relief of symptoms and signs of ankylosing spondylitis
4. Relief of acute pain in adults (post-surgery, post-tooth extraction pain relief)
5. Primary dysmenorrhea
3. Dosage and dosage
The minimum recommended dose of this drug should be adjusted depending on the patient, and can be administered regardless of meals.
○ Adults:
1. Osteoarthritis (degenerative arthritis): Take 200 mg of celecoxib once a day, or 100 mg twice a day.
2. Rheumatoid arthritis: Take 100 mg or 200 mg twice a day as celecoxib.
3. Ankylosing spondylitis (AS): Celecoxib is administered at 200 mg once a day, or divided into 100 mg twice a day. If no effect is observed after 6 weeks, the dose may be increased to 400 mg per day. If no effect is observed after 6 weeks of administering 400 mg per day, other treatment options should be considered.
4. Acute pain and primary dysmenorrhea: The initial recommended dose is 400 mg of celecoxib, and if necessary, an additional 200 mg is administered on the first day of administration. From the second day of administration, if necessary, administer 200 mg twice a day as recommended dose.
○ Patients with hepatic impairment: For patients with moderate hepatic impairment (Child-Pugh Class II), the dose should be reduced to approximately 50% of the daily recommendation.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular thrombotic events: This drug may increase the risk of serious cardiovascular thrombotic events, myocardial infarction and stroke, which can be fatal. Similar risks may occur with all nonsteroidal anti-inflammatory drugs. This risk may increase depending on the administered dose and administration period. The relative increase from baseline in serious cardiovascular thrombotic events due to NSAID drugs was similar regardless of the presence or absence of cardiovascular disease or cardiovascular risk factors, but the absolute incidence rate was observed to be higher due to the baseline increased rate of cardiovascular thrombotic events. To minimize the potential risk of adverse cardiovascular events in patients treated with this drug, it should be used at the lowest effective dose and for the shortest possible period. Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance of the measures to be taken if signs and symptoms of serious cardiovascular toxicity (chest pain, shortness of breath, weakness, slurred speech) develop.
3) Gastrointestinal risk: Upper and lower gastrointestinal perforation, ulceration, or bleeding occurred in patients treated with this drug. Nonsteroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration. While administering this drug, patients should be carefully monitored for signs and symptoms of gastrointestinal ulcers or bleeding. If suggestive symptoms including pain in the solar plexus, indigestion, melena, or hematemesis or severe gastrointestinal adverse reactions are suspected, additional evaluation and treatment should be performed immediately. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. Do not administer to the following patients
1) Patients who have or have a history of hypersensitivity to this drug or its components
2) Patients with allergic reactions to sulfonamides
3) Patients with a history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors)
4) Patients with severe liver impairment
5) Patients with severe renal impairment (patients with creatinine clearance <30 mL/min)
6) Patients with active peptic ulcer or gastrointestinal bleeding
7) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
8) Patients with congestive heart failure (NYHA II - IV)
9) Patients with established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
10) Women who are pregnant or may be pregnant
11) Nursing mothers
12) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
13) Patients with hyperkalemia
14) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients:
1) Patients with hepatic impairment or a history of it
2) Patients with renal impairment or a history of it (patients with creatinine clearance <60mL/min)
3) Patients with bronchial asthma
4) Patients with heart failure or a history of it
5) Patients with high blood pressure or a history of it
6) Patients with fluid retention or a history of edema
7) Patients taking diuretics or ACE inhibitors
8) Patients at risk of hypovolemia
9) Dehydrated patient
10) Elderly people
11) Patients with a history of peptic ulcer or gastrointestinal bleeding
12) Patients with high risk factors for adverse cardiovascular events (heart attack, stroke, etc.) (e.g. high blood pressure, hyperlipidemia, diabetes, smoking, etc.), patients with cardiovascular disease or a history thereof
13) Patients with difficult metabolism by CYP2C9
14) Patients with blood coagulation disorders or receiving anticoagulants
15) Women planning to become pregnant (taking this drug may impair female fertility)
16) Diabetics
4. Adverse reactions
1) Clinical trials
(1) Table 1 below shows adverse reactions that were reported at a higher rate than the placebo group, with an incidence of >0.01% in the celecoxib group in 12 placebo- and/or active drug-controlled clinical trials in adults administered doses ranging from 100 mg to 800 mg per day for up to 12 weeks. The incidence was calculated based on the latest pooled results of 89 randomized, controlled clinical trials corresponding to clinical exposure of 38,102 patients taking celecoxib.
Definition of frequency: very common (≥ 10%), common (≥ 1%, < 10%), uncommon (≥ 0.1%, < 1%), rare (≥ 0.01%, < 0.1%), very rare (< 0.01%)
The adverse reactions in Table 1 were classified by organ system and listed by frequency of occurrence.
[Table 1]. Adverse reactions in 12 placebo- and/or active drug-controlled clinical trials in adults and incidence estimates based on 89 randomized, controlled trials of pain and inflammation at doses ranging from 25 mg to 800 mg per day
*Refer to manual
(2) According to a comparative clinical trial with placebo or active control drug, the rate of discontinuation of drug administration due to adverse reactions was 7.1% in the drug administration group and 6.1% in the placebo group. The most frequent adverse reactions that led to discontinuation of this drug were indigestion and abdominal pain. Regardless of the causal relationship with this drug, adverse reactions reported in adults after administration of this drug are as follows.
① Gastrointestinal system: indigestion (8.8%), diarrhea (5.6%), irritable bowel syndrome, increased frequency of bowel movements, occasional abdominal pain, epigastric pain, flatulence, nausea, constipation, diverticulitis, dysphagia, burping, esophagitis, gastroenteritis, gastrointestinal ulcer, gastroesophageal reflux, stomach discomfort, gastrointestinal disorders, hemorrhoids, hiatal hernia, bloody stool, dry mouth, stomatitis, Back pain, dental disease, vomiting, worsening of gastrointestinal inflammation, erosion of the corner of the mouth, rarely ileus, intestinal perforation, gastrointestinal bleeding, hemorrhagic colitis, esophageal perforation, pancreatitis, intestinal obstruction, post-tooth extraction alveolar osteitis, intestinal anastomosis ulcer, melena, glossitis, aphthous stomatitis, blistering of the oral mucosa, numbness of the mouth, and pain in the oral cavity may occur.
② Central and peripheral nervous system: headache (15.8%), occasional dizziness, leg cramps, hypertonia, decreased perception, migraine, neuralgia, neuropathy, paresthesia, cerebral infarction, rarely aseptic meningitis, ataxia, suicide, loss of smell, anosmia.
③ Whole body: Occasionally back pain, exacerbation of allergies, allergic reaction, asthenia, chest pain, fluid retention/peripheral edema, systemic edema, facial edema, fatigue, malaise, fever, facial flushing, influenza syndrome, pain, peripheral pain, rarely sepsis, sudden death, anaphylactoid reaction, angioedema.
④ Mental nervous system: Occasionally insomnia, anorexia, anxiety, increased appetite, depression, nervous irritability, drowsiness, fatal intracranial hemorrhage, confusion, hallucinations, worsening of epilepsy.
⑤ Respiratory system: upper respiratory tract infection (8.1%), sinusitis (5.0%), sometimes pharyngitis, rhinitis, bronchitis, bronchospasm, worsening bronchospasm, cough, dyspnea, laryngitis, pneumonia, rarely nosebleeds, dysphonia
⑥ Skin and appendages: Bullous dermatitis, ecchymosis, occasional rash, alopecia, dermatitis, nail disease, photosensitivity reaction, pruritus, erythematous rash, maculopapular rash, skin disease, dry skin, increased sweating, urticaria, erythema multiforme, exfoliative dermatitis, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), Eczema, lipoma, allergic dermatitis, rarely petechiae, dandruff, drug rash with eosinophilia and systemic symptoms (DRESS or hypersensitivity reaction syndrome)
⑦ Cardiovascular system: Arrhythmia, ventricular hypertrophy, sometimes exacerbated hypertension, hypertension, angina pectoris, unstable angina, coronary artery disease, myocardial infarction, heart failure, congestive heart failure, palpitations, tachycardia, stroke, aortic regurgitation, hematoma, sinus bradycardia, rarely syncope, ventricular fibrillation, pulmonary embolism, cerebrovascular attack, peripheral gangrene, thrombophlebitis, vasculitis, deep vein thrombosis, cerebral hemorrhage
⑧ Infections: Upper respiratory infection, erysipelas, wound infection, gingivitis, sometimes herpes simplex, herpes zoster, bacterial infection, fungal infection, soft tissue infection, viral infection, moniliasis, genital moniliasis, otitis media.
⑨ Reproductive system: breast tenderness, menopausal symptoms, sometimes thoracic mammary fibromatosis, thoracic neoplasm (women), chest pain (women), dysmenorrhea, menstrual disorders, vaginal bleeding, vaginitis, prostate disorder, ovarian cystitis
⑩ Ears: Sometimes hearing loss, ear abnormalities, ear pain, tinnitus, hearing loss
⑪ Liver and biliary system: Occasionally abnormal liver function, increased ALT, increased AST, increased γ-GTP, increased ALP, positive urinary urobilinogen, rarely cholelithiasis, hepatitis, jaundice, liver failure, fulminant hepatitis, liver necrosis.
⑫ Metabolism and nutrition: Increased blood sodium, increased blood potassium, sometimes increased BUN, increased CPK, diabetes, hypercholesterolemia, hyperglycemia, hypokalemia, hyperkalemia, increased NPN, increased creatinine, increased alkaline phosphatase, weight gain, loss of appetite, increased LDH, rarely hypoglycemia, hyponatremia
⑬ Skeletal muscle system: Synovial cyst, sometimes arthralgia, arthrosis, skeletal abnormalities, muscle pain, cervical tension, synovitis, tendinitis, myositis, leg cramps, fractures, tendon rupture, rarely back pain, muscle stiffness.
⑭ Blood system: decreased hematocrit, increased hemoglobin, sometimes ecchymosis, epistaxis, thrombocytosis, anemia, rarely thrombocytopenia, agranulocytosis, aplastic anemia, pancytopenia, leukopenia
⑮ Site of administration: Occasionally cellulitis, contact dermatitis, injection site reaction, skin nodules
- Special organs: sometimes taste buds
- Urinary tract: Occasionally albuminuria, cystitis, hematuria, dysuria, urinary frequency, nephrolithiasis, urinary incontinence, urinary tract infection.
- Eyes: Sometimes blurred vision, cataracts, conjunctivitis, eye pain, glaucoma, rarely intraocular hemorrhage, retinal artery or vein occlusion.
- Kidney: Increased blood creatinine, increased β2-microglobulin, occasionally increased NAG, positive urinary occult blood, positive urine protein, rarely renal dysfunction, acute renal failure, interstitial nephritis.
2) Domestic post-marketing survey results
(1) As a result of a post-marketing use results survey conducted in Korea for 6 years, 338 adverse reactions were reported in 305 cases (5.40%) out of a total of 5,648 cases, regardless of causal relationship with the drug. Indigestion was the most common with 155 cases (2.74%), followed by facial edema in 54 cases (0.96%), abdominal pain in 33 cases (0.58%), nausea in 13 cases (0.23%), peripheral edema and rash in 12 cases each (0.21%), diarrhea in 10 cases (0.18%), and insomnia in 7 cases (0.12%).
(2) As other adverse reactions, headache and dizziness were reported in 5 cases each (0.09%), constipation, stomach ulcers, urticaria, and anemia were reported in 2 cases each (0.04%), and dry mouth, ulcerative stomatitis, gastritis, allergy, back pain, chest pain, hyperlipidemia, diabetes, weight gain, fracture, joint pain, RA factor positivity, shingles, pneumonia, difficulty breathing, elevation of ALT, and hearing loss were reported. 1 case (0.02%) was reported.
3) Overseas post-marketing survey results
Adverse reactions identified in post-marketing experience are as follows. Although these adverse reactions were confirmed in post-marketing reports, clinical trial data were referenced to assess frequency. As above, the incidence is based on the combined results of clinical trials representing exposure in 38,102 patients.
Definition of frequency: very common (≥ 10%), common (≥ 1%, < 10%), uncommon (≥ 0.1%, < 1%), rare (≥ 0.01%, < 0.1%), very rare (< 0.01%), frequency unknown (cannot be evaluated based on existing data)
(1) Immune system: very rare - anaphylactic reaction
(2) Mental world: rarely - hallucinations
(3) Nervous system: Very rare – cerebral hemorrhage, aseptic meningitis, loss of taste, loss of smell.
(4) Eyes: Uncommon - Conjunctivitis
(5) Blood vessels: very rare - vasculitis
(6) Respiration, chest and mediastinum: Rare - pulmonary embolism, interstitial pneumonia.
(7) Gastrointestinal tract: Rare - gastrointestinal bleeding.
(8) Hepatobiliary: rarely - hepatitis
Very rare - liver failure, fulminant hepatitis, liver necrosis, cholestasis, cholestatic hepatitis, jaundice.
(9) Skin and subcutaneous tissue: Rare - photosensitivity reaction.
Very rare - Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), exfoliative dermatitis.
(10) Renal and urinary system: Rare - acute renal failure, hyponatremia.
Very rare - tubulointerstitial nephritis, nephrotic syndrome, microlesion glomerulonephritis (11) Reproductive system and breast: rare - menstrual disorders
Frequency unknown† - Female infertility (reduced female fertility)
(12) Systemic body and administration site: Uncommon - chest pain
†Women planning pregnancy were excluded from all clinical trials, so it is not appropriate to refer to clinical trial data for the frequency of this adverse reaction.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. As the dose and exposure period of this drug increase, the cardiovascular risk increases, so administer it at the lowest effective dose for the shortest possible period. In particular, patients with osteoarthritis (degenerative arthritis) should be re-evaluated periodically.
2) Gastrointestinal effects: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, concurrent use of nonsteroidal anti-inflammatory drugs or aspirin, alcohol consumption, cardiovascular disease, smoking, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
3) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. Because inhibition of prostaglandin synthesis may cause deterioration of renal function and fluid retention, this drug should be administered with caution in patients with a history of heart failure, left ventricular dysfunction, or hypertension, or in patients with edema or fluid retention. Additionally, patients taking diuretics or at risk of hypovolemia for other reasons should also exercise caution when administering this drug.
5) Effects on kidneys: Non-steroidal anti-inflammatory drugs, including this drug, may cause nephrotoxicity. The renal effects of this drug in clinical trials were similar to those observed with the nonsteroidal anti-inflammatory drugs used as reference drugs. Long-term use of non-steroidal anti-inflammatory drugs may cause renal papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients at greatest risk of nephrotoxicity, such as patients with renal dysfunction, heart failure, liver dysfunction, patients taking diuretics, ACE inhibitors, or angiotensin II antagonists, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Effects on the liver: Not studied in patients with severe hepatic impairment (Child-Pugh Class C). Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal or required liver transplantation) were rarely reported with the administration of non-steroidal anti-inflammatory drugs, including this drug. For patients with symptoms and/or signs suggestive of liver function abnormality or for patients with abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration of this drug should be discontinued.
8) If symptoms or signs of anemia or blood loss appear due to long-term administration of this drug, a hemoglobin level or hematocrit level test should be performed. This drug generally does not affect platelet counts, prothrombin time (PT), or partial thromboplastin time (PTT), and does not inhibit platelet aggregation at recommended doses.
9) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, administration of this drug should be discontinued.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
11) Skin reaction: This drug is a sulfonamide class drug, and can cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms and may occur even in patients without a history of sulfa drug allergy. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and signs and should discontinue drug administration at the first symptoms and signs of hypersensitivity reactions such as skin rash, mucosal lesions or blisters, fever, and itching.
12) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
13) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
14) Due to the pharmacological properties of this drug, it may suppress fever and other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
15) For patients showing symptoms of severe dehydration, administer medication after providing fluids and observe carefully.
16) For acute pain relief in adults (pain relief after surgery or tooth extraction), it is used for a short period of time (within 1 week).
17) Two large-scale controlled clinical trials in which COX-2-selective non-steroidal anti-inflammatory drugs were administered to treat pain in the first 10 to 14 days immediately after coronary artery bypass grafting (CABG) showed an increase in the incidence of myocardial infarction and stroke.
18) Clinical tests (urinalysis, blood tests, kidney function tests, liver function tests, electrocardiograms, fecal occult blood tests, etc.) should be conducted on a regular or as needed basis, and if abnormalities are found, appropriate measures such as withdrawal of medication or discontinuation of administration should be taken.
19) Patients who experience dizziness or drowsiness after taking this drug should avoid driving or operating machinery.
20) This drug has no effect on platelet function, so it cannot be a substitute for acetylsalicylic acid for the prevention of cardiovascular thromboembolic disease. Because this drug does not inhibit platelet aggregation, patients receiving antiplatelet therapy (e.g., acetylsalicylic acid) should not discontinue treatment.
21) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
22) Cross-sensitivity: Patients who are sensitive to one NSAID may also be sensitive to other NSAIDs.
23) Patients with autoimmune diseases (e.g., patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)) may have an increased risk of developing aseptic meningitis when taking this drug.
24) Hyperkalemia may occur when this drug is administered to diabetic patients or in combination with drugs that increase blood potassium levels, so regular monitoring of potassium levels is necessary in these cases.
25) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
6. Interaction
1) This drug is mainly metabolized by CYP 2C9 in the liver, so caution should be exercised when co-administered with drugs that inhibit CYP 2C9. In patients suspected to be poor metabolizers of CYP 2C9 based on previous history or experience with other CYP 2C9 substrates, caution should be exercised when administering this drug as plasma concentrations may increase abnormally due to decreased clearance. Consider starting treatment at half the lowest recommended dose.
Co-administration of this drug with CYP 2C9 inhibitors may increase the plasma concentration of this drug. Therefore, when this drug is co-administered with a CYP 2C9 inhibitor, a dose reduction may be necessary.
Co-administration of this drug with CYP 2C9 inducers such as rifampicin, carbamazepine, and barbiturates may decrease the plasma concentration of this drug. Therefore, when this drug is co-administered with a CYP 2C9 inducer, an increase in the dose of this drug may be necessary.
2) Fluconazole and Ketoconazole: When fluconazole 200 mg is co-administered once a day, the metabolism of this drug through CYP 2C9 is inhibited by fluconazole, which doubles the blood concentration of this drug. Therefore, when starting concurrent use of this drug, administer at half the recommended dose.
Ketoconazole, a CYP 3A4 inhibitor, did not show clinically significant inhibition of the metabolism of this drug.
3) CYP 2D6: According to pharmacokinetic clinical studies and in vitro studies, this drug was found to be an inhibitor but not a substrate of CYP 2D6, so it may interact in vivo with drugs metabolized by CYP 2D6. When administered together with this drug, blood levels of antidepressants (tricyclics and SSRIs), neuroleptics, antiarrhythmic drugs, and dextromethorphan, which are CYP 2D6 substrates, may increase. When starting concomitant administration of this drug, a dose reduction of these drugs may be necessary, and when concomitant administration of this drug is discontinued, a dose increase of these drugs may be necessary.
4) In vitro studies confirmed that this drug partially inhibits metabolism mediated by CYP 2C19. The clinical significance of these results is unknown, but drugs metabolized by CYP 2C19 include diazepam, citalopram, and imipramine.
5) Antihypertensive drugs, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (also known as angiotensin receptor blockers, ARBs), diuretics, and beta-blockers: Inhibition of prostaglandins may reduce the effectiveness of antihypertensive drugs, including ACEIs, ARBs, diuretics, and beta-blockers. Caution should be exercised regarding this interaction when coadministering beta-blockers. When NSAIDs, including selective COX-2 inhibitors (celecoxib), are coadministered with ACE inhibitors, angiotensin II receptor antagonists, or diuretics to volume-depleted patients, including those with reduced renal function, the elderly, or those taking diuretics, it may lead to decreased renal function, including acute renal failure. Therefore, caution should be exercised when administering this combination, especially to the elderly. Patients should be adequately hydrated, and renal function should be monitored regularly after starting this combination treatment.
Lisinopril Study Results: In a 28-day controlled clinical trial of lisinopril in patients with hypertension stage I and II, co-administration of 200 mg twice daily (BID) did not result in a clinically significant increase in mean daily systolic or diastolic blood pressure as measured by 24-hour ambulatory blood pressure monitoring compared with placebo. Among patients co-administered with 200 mg BID, 48% had no response to lisinopril (defined as diastolic blood pressure > 90 mmHg or > 10% increase in diastolic blood pressure compared to baseline) at the final clinical visit, compared to 27% of patients co-administered with placebo. This was a statistically significant difference.
6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
7) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of NSAIDs. It can be administered in combination with low-dose aspirin (less than 325 mg per day), but it has been reported that the incidence of gastrointestinal adverse reactions (gastrointestinal ulcers) or other gastrointestinal complications is higher than when this drug is administered alone. When aspirin is administered as preventive therapy for the cardiovascular system, this drug does not have an effect on platelets and therefore cannot be used as a substitute for aspirin.
8) Dextromethorphan and metoprolol: When 200 mg of this drug was administered twice a day, the plasma concentrations of dextromethorphan and metoprolol (CYP 2D6 substrates) increased by 2.6-fold and 1.5-fold, respectively. This increase is due to the drug's inhibition of CYP 2D6 substrate metabolism through CYP 2D6. Therefore, when starting treatment with this drug, it may be necessary to reduce the dosage of drugs that are CYP 2D6 substrates, or when stopping treatment with this drug, the dosage of drugs that are CYP 2D6 substrates may need to be increased.
9) Lithium: When this drug and lithium are co-administered in healthy adults, the serum lithium concentration increases by about 17% and the renal clearance of lithium may decrease due to inhibition of prostaglandin synthesis in the kidney. Therefore, patients receiving lithium should be carefully observed for signs of lithium toxicity when starting or stopping treatment with this drug.
10) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered concurrently with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate. When celecoxib was administered in combination with methotrexate (rheumatoid treatment dose) to patients with rheumatoid arthritis, there was no significant effect. However, if the two drugs are coadministered, appropriate monitoring for methotrexate-related toxicity should be considered.
11) Oral anticoagulants: When NSAIDs and oral anticoagulants are administered together, the risk of bleeding may increase, so they should be administered with caution. Oral anticoagulants include warfarin/coumarins and newer anticoagulants (e.g., apixaban, dabigatran, rivaroxaban). For gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
In a study in which 2-5 mg of warfarin per day was administered to healthy subjects to determine the effect of this drug on the anticoagulant activity of warfarin, there was no effect on the anticoagulant activity as measured by prothrombin time. However, post-marketing studies have shown that serious bleeding associated with prolongation of the prothrombin time, which may be fatal, has been reported in patients receiving this drug in combination with warfarin, especially in the elderly.
Prolongation of prothrombin time (INR) has been reported; therefore, anticoagulation/INR should be monitored after starting or changing the dose in patients taking warfarin/coumarin anticoagulants.
12) Cyclosporine: Since the nephrotoxicity of cyclosporine or tacrolimus may increase due to co-administration of non-steroidal anti-inflammatory drugs and cyclosporine or tacrolimus, renal function should be monitored when co-administered with these drugs.
13) When this drug was taken with a high-fat meal, the peak plasma concentration was delayed by about 1-2 hours, and the total absorption (AUC) increased by 10-20%.
14) When this drug was administered in combination with antacids containing aluminum or magnesium, there was a 37% decrease in peak blood concentration and a 10% decrease in total absorption.
15) In addition to low-dose aspirin (less than 325 mg per day), co-administration with other non-steroidal anti-inflammatory drugs should not be performed as the risk of adverse reactions may increase.
16) Corticosteroids: There is a risk of increased gastrointestinal side effects (e.g. ulcers, bleeding). There is a particular risk for elderly people (over 65 years of age).
17) Oral contraceptives: In an interaction study, this drug did not have a clinically significant effect on the pharmacokinetics of a combined oral contraceptive (norethindrone 1 mg/ethinyl estradiol 0.035 mg).
18) When used together with fluvastatin, the blood concentration of this drug and fluvastatin may increase.
19) Other drugs: No clinically significant interactions were observed when this drug was co-administered with omeprazole, glibenclamide (glyburide), phenytoin, and tolbutamide.
7. Administration to pregnant and lactating women
1) In experiments on rats, it was reported that this drug does not delay parturition. However, the effect of this drug on labor and delivery in pregnant women is not known.
2) In a rabbit embryo/fetal development test, the rate of fetal abnormalities such as rib fusion and sternal segment fusion and the incidence of ventricular septal defects rarely increased when administered orally at doses above 150 mg/kg/day (about twice the AUC0-24 when administered to humans at 200 mg twice a day). In a rat embryo/fetal development study, a dose-dependent increase in diaphragmatic hernia was observed in fetuses when administered orally at a dose of 30 mg/kg/day or more (equivalent to approximately 6 times the AUC0-24 when administered to humans at 200 mg twice a day) in one of the two tests. In addition, when administered to rats in doses exceeding 50 mg/kg/day (a dose equivalent to approximately 6 times the AUC0-24 when administered to humans at 200 mg twice a day), it caused pre-implantation loss, post-implantation loss, and decreased fetal survival rate. Such toxicity was not observed in pregnancy 2 weeks after discontinuation of drug administration.
3) There is no clinical data on administering this drug to pregnant women. In animal experiments (rabbits and rats), administration of this drug has shown reproductive toxicity, including teratogenicity, but the potential risk to human pregnancy is unknown. Also, like other drugs that inhibit prostaglandin synthesis, this drug may cause uterine atony or premature closure of the fetal ductus arteriosus when administered late in pregnancy, so this drug should not be administered to pregnant women or women who may become pregnant. If pregnancy is confirmed while taking this drug, administration of this drug should be discontinued. This medicine is used in pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
4) The use of non-steroidal anti-inflammatory drugs, including this drug, may interfere with or delay follicular rupture due to their mechanism of action, which may cause reversible infertility in some women. Therefore, women who have difficulty conceiving or are undergoing infertility tests should consider discontinuing the use of non-steroidal anti-inflammatory drugs, including this drug.
5) Inhibition of prostaglandin synthesis may have an adverse effect on pregnancy. Epidemiological studies have shown that the risk of spontaneous miscarriage increases after taking drugs that inhibit prostaglandin synthesis in early pregnancy. Animal tests showed that implantation failure increased when drugs that inhibit prostaglandin synthesis were administered.
6) Administration of non-steroidal anti-inflammatory drugs during the second or third trimester of pregnancy may cause abnormalities in fetal kidney function, which may lead to a decrease in the amount of amniotic fluid or oligohydramnios in severe cases. These effects may appear immediately after starting drug administration and are generally reversible. Amniotic fluid volume should be closely monitored in pregnant women taking this drug.
7) This drug is excreted in rat breast milk at a concentration similar to that in plasma. Based on limited data from one subject, it is believed that this drug may also pass into human breast milk. Many drugs not only pass into breast milk, but if they do so, there is concern that serious adverse reactions may occur in infants. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.
8. Administration to children
Safety and effectiveness in children and adolescents under 18 years of age have not been established.
9. Administration to elderly people
1) Elderly people are more likely to have decreased renal function, liver function, and especially cardiac function, so appropriate observation is required when administering this drug to the elderly.
2) According to clinical trials, there was no significant difference in effectiveness between elderly and young subjects. In clinical trials comparing kidney function (GFR, BUN, creatinine) and platelet function (bleeding time, degree of platelet aggregation), there were no differences between older and younger subjects. However, as with other NSAIDs, including selective COX-2 inhibitors, spontaneous post-marketing adverse reactions of fatal gastrointestinal adverse events and acute renal dysfunction were more frequently reported in elderly patients.
3) In general, dosage adjustment is not required for the elderly, but if the body weight is less than 50 kg, administration should be started at the lowest dose.
10. Effect on clinical test values
1) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should regularly undergo complete blood count (CBC) and physicochemical tests. If abnormal liver function test results or renal function test results persist or worsen, treatment with this drug should be discontinued.
2) As with other non-steroidal anti-inflammatory drugs, BUN elevations were observed more frequently than placebo in clinical trials, but clinical significance was not confirmed.
11. Treatment in case of overdose
1) Overdose of this drug has not been reported during clinical trials. No serious toxicity occurred in 12 patients when administered at doses up to 2,400 mg/day for up to 10 days.
2) Symptoms of overdosage of non-steroidal anti-inflammatory drugs generally include lethargy, drowsiness, nausea, vomiting, and upper abdominal pain, and can be recovered with auxiliary treatment. Gastrointestinal bleeding may also occur, and in rare cases, hypertension, acute renal failure, respiratory depression, and coma may occur.
3) Symptomatic and supportive treatment is usually performed, and there is no specific antidote.
4) If symptoms appear within 4 hours of taking the drug or if a very large dose is taken, vomiting, activated charcoal (60-100 g per kg for adults, 1-2 g per kg for children), and osmotic diarrhea can be used.
5) Treatments such as hemodialysis, forced diuresis, urinary alkalinization, and blood perfusion are not useful due to the high protein binding rate of celecoxib.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Celecoxib (EP)----200mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: sodium lauryl sulfate, titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, croscarmellose sodium, povidone, polyethylene glycol 6000, hypromellose
2. Effectiveness
1. Alleviation of symptoms and signs of osteoarthritis (degenerative arthritis)
2. Relief of symptoms and signs of rheumatoid arthritis
3. Relief of symptoms and signs of ankylosing spondylitis
4. Relief of acute pain in adults (post-surgery, post-tooth extraction pain relief)
5. Primary dysmenorrhea
3. Dosage and dosage
The minimum recommended dose of this drug should be adjusted depending on the patient, and can be administered regardless of meals.
○ Adults:
1. Osteoarthritis (degenerative arthritis): Take 200 mg of celecoxib once a day, or 100 mg twice a day.
2. Rheumatoid arthritis: Take 100 mg or 200 mg twice a day as celecoxib.
3. Ankylosing spondylitis (AS): Celecoxib is administered at 200 mg once a day, or divided into 100 mg twice a day. If no effect is observed after 6 weeks, the dose may be increased to 400 mg per day. If no effect is observed after 6 weeks of administering 400 mg per day, other treatment options should be considered.
4. Acute pain and primary dysmenorrhea: The initial recommended dose is 400 mg of celecoxib, and if necessary, an additional 200 mg is administered on the first day of administration. From the second day of administration, if necessary, administer 200 mg twice a day as recommended dose.
○ Patients with hepatic impairment: For patients with moderate hepatic impairment (Child-Pugh Class II), the dose should be reduced to approximately 50% of the daily recommendation.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular thrombotic events: This drug may increase the risk of serious cardiovascular thrombotic events, myocardial infarction and stroke, which can be fatal. Similar risks may occur with all nonsteroidal anti-inflammatory drugs. This risk may increase depending on the administered dose and administration period. The relative increase from baseline in serious cardiovascular thrombotic events due to NSAID drugs was similar regardless of the presence or absence of cardiovascular disease or cardiovascular risk factors, but the absolute incidence rate was observed to be higher due to the baseline increased rate of cardiovascular thrombotic events. To minimize the potential risk of adverse cardiovascular events in patients treated with this drug, it should be used at the lowest effective dose and for the shortest possible period. Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance of the measures to be taken if signs and symptoms of serious cardiovascular toxicity (chest pain, shortness of breath, weakness, slurred speech) develop.
3) Gastrointestinal risk: Upper and lower gastrointestinal perforation, ulceration, or bleeding occurred in patients treated with this drug. Nonsteroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration. While administering this drug, patients should be carefully monitored for signs and symptoms of gastrointestinal ulcers or bleeding. If suggestive symptoms including pain in the solar plexus, indigestion, melena, or hematemesis or severe gastrointestinal adverse reactions are suspected, additional evaluation and treatment should be performed immediately. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. Do not administer to the following patients
1) Patients who have or have a history of hypersensitivity to this drug or its components
2) Patients with allergic reactions to sulfonamides
3) Patients with a history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors)
4) Patients with severe liver impairment
5) Patients with severe renal impairment (patients with creatinine clearance <30 mL/min)
6) Patients with active peptic ulcer or gastrointestinal bleeding
7) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
8) Patients with congestive heart failure (NYHA II - IV)
9) Patients with established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
10) Women who are pregnant or may be pregnant
11) Nursing mothers
12) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
13) Patients with hyperkalemia
14) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients:
1) Patients with hepatic impairment or a history of it
2) Patients with renal impairment or a history of it (patients with creatinine clearance <60mL/min)
3) Patients with bronchial asthma
4) Patients with heart failure or a history of it
5) Patients with high blood pressure or a history of it
6) Patients with fluid retention or a history of edema
7) Patients taking diuretics or ACE inhibitors
8) Patients at risk of hypovolemia
9) Dehydrated patient
10) Elderly people
11) Patients with a history of peptic ulcer or gastrointestinal bleeding
12) Patients with high risk factors for adverse cardiovascular events (heart attack, stroke, etc.) (e.g. high blood pressure, hyperlipidemia, diabetes, smoking, etc.), patients with cardiovascular disease or a history thereof
13) Patients with difficult metabolism by CYP2C9
14) Patients with blood coagulation disorders or receiving anticoagulants
15) Women planning to become pregnant (taking this drug may impair female fertility)
16) Diabetics
4. Adverse reactions
1) Clinical trials
(1) Table 1 below shows adverse reactions that were reported at a higher rate than the placebo group, with an incidence of >0.01% in the celecoxib group in 12 placebo- and/or active drug-controlled clinical trials in adults administered doses ranging from 100 mg to 800 mg per day for up to 12 weeks. The incidence was calculated based on the latest pooled results of 89 randomized, controlled clinical trials corresponding to clinical exposure of 38,102 patients taking celecoxib.
Definition of frequency: very common (≥ 10%), common (≥ 1%, < 10%), uncommon (≥ 0.1%, < 1%), rare (≥ 0.01%, < 0.1%), very rare (< 0.01%)
The adverse reactions in Table 1 were classified by organ system and listed by frequency of occurrence.
[Table 1]. Adverse reactions in 12 placebo- and/or active drug-controlled clinical trials in adults and incidence estimates based on 89 randomized, controlled trials of pain and inflammation at doses ranging from 25 mg to 800 mg per day
*Refer to manual
(2) According to a comparative clinical trial with placebo or active control drug, the rate of discontinuation of drug administration due to adverse reactions was 7.1% in the drug administration group and 6.1% in the placebo group. The most frequent adverse reactions that led to discontinuation of this drug were indigestion and abdominal pain. Regardless of the causal relationship with this drug, adverse reactions reported in adults after administration of this drug are as follows.
① Gastrointestinal system: indigestion (8.8%), diarrhea (5.6%), irritable bowel syndrome, increased frequency of bowel movements, occasional abdominal pain, epigastric pain, flatulence, nausea, constipation, diverticulitis, dysphagia, burping, esophagitis, gastroenteritis, gastrointestinal ulcer, gastroesophageal reflux, stomach discomfort, gastrointestinal disorders, hemorrhoids, hiatal hernia, bloody stool, dry mouth, stomatitis, Back pain, dental disease, vomiting, worsening of gastrointestinal inflammation, erosion of the corner of the mouth, rarely ileus, intestinal perforation, gastrointestinal bleeding, hemorrhagic colitis, esophageal perforation, pancreatitis, intestinal obstruction, post-tooth extraction alveolar osteitis, intestinal anastomosis ulcer, melena, glossitis, aphthous stomatitis, blistering of the oral mucosa, numbness of the mouth, and pain in the oral cavity may occur.
② Central and peripheral nervous system: headache (15.8%), occasional dizziness, leg cramps, hypertonia, decreased perception, migraine, neuralgia, neuropathy, paresthesia, cerebral infarction, rarely aseptic meningitis, ataxia, suicide, loss of smell, anosmia.
③ Whole body: Occasionally back pain, exacerbation of allergies, allergic reaction, asthenia, chest pain, fluid retention/peripheral edema, systemic edema, facial edema, fatigue, malaise, fever, facial flushing, influenza syndrome, pain, peripheral pain, rarely sepsis, sudden death, anaphylactoid reaction, angioedema.
④ Mental nervous system: Occasionally insomnia, anorexia, anxiety, increased appetite, depression, nervous irritability, drowsiness, fatal intracranial hemorrhage, confusion, hallucinations, worsening of epilepsy.
⑤ Respiratory system: upper respiratory tract infection (8.1%), sinusitis (5.0%), sometimes pharyngitis, rhinitis, bronchitis, bronchospasm, worsening bronchospasm, cough, dyspnea, laryngitis, pneumonia, rarely nosebleeds, dysphonia
⑥ Skin and appendages: Bullous dermatitis, ecchymosis, occasional rash, alopecia, dermatitis, nail disease, photosensitivity reaction, pruritus, erythematous rash, maculopapular rash, skin disease, dry skin, increased sweating, urticaria, erythema multiforme, exfoliative dermatitis, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), Eczema, lipoma, allergic dermatitis, rarely petechiae, dandruff, drug rash with eosinophilia and systemic symptoms (DRESS or hypersensitivity reaction syndrome)
⑦ Cardiovascular system: Arrhythmia, ventricular hypertrophy, sometimes exacerbated hypertension, hypertension, angina pectoris, unstable angina, coronary artery disease, myocardial infarction, heart failure, congestive heart failure, palpitations, tachycardia, stroke, aortic regurgitation, hematoma, sinus bradycardia, rarely syncope, ventricular fibrillation, pulmonary embolism, cerebrovascular attack, peripheral gangrene, thrombophlebitis, vasculitis, deep vein thrombosis, cerebral hemorrhage
⑧ Infections: Upper respiratory infection, erysipelas, wound infection, gingivitis, sometimes herpes simplex, herpes zoster, bacterial infection, fungal infection, soft tissue infection, viral infection, moniliasis, genital moniliasis, otitis media.
⑨ Reproductive system: breast tenderness, menopausal symptoms, sometimes thoracic mammary fibromatosis, thoracic neoplasm (women), chest pain (women), dysmenorrhea, menstrual disorders, vaginal bleeding, vaginitis, prostate disorder, ovarian cystitis
⑩ Ears: Sometimes hearing loss, ear abnormalities, ear pain, tinnitus, hearing loss
⑪ Liver and biliary system: Occasionally abnormal liver function, increased ALT, increased AST, increased γ-GTP, increased ALP, positive urinary urobilinogen, rarely cholelithiasis, hepatitis, jaundice, liver failure, fulminant hepatitis, liver necrosis.
⑫ Metabolism and nutrition: Increased blood sodium, increased blood potassium, sometimes increased BUN, increased CPK, diabetes, hypercholesterolemia, hyperglycemia, hypokalemia, hyperkalemia, increased NPN, increased creatinine, increased alkaline phosphatase, weight gain, loss of appetite, increased LDH, rarely hypoglycemia, hyponatremia
⑬ Skeletal muscle system: Synovial cyst, sometimes arthralgia, arthrosis, skeletal abnormalities, muscle pain, cervical tension, synovitis, tendinitis, myositis, leg cramps, fractures, tendon rupture, rarely back pain, muscle stiffness.
⑭ Blood system: decreased hematocrit, increased hemoglobin, sometimes ecchymosis, epistaxis, thrombocytosis, anemia, rarely thrombocytopenia, agranulocytosis, aplastic anemia, pancytopenia, leukopenia
⑮ Site of administration: Occasionally cellulitis, contact dermatitis, injection site reaction, skin nodules
- Special organs: sometimes taste buds
- Urinary tract: Occasionally albuminuria, cystitis, hematuria, dysuria, urinary frequency, nephrolithiasis, urinary incontinence, urinary tract infection.
- Eyes: Sometimes blurred vision, cataracts, conjunctivitis, eye pain, glaucoma, rarely intraocular hemorrhage, retinal artery or vein occlusion.
- Kidney: Increased blood creatinine, increased β2-microglobulin, occasionally increased NAG, positive urinary occult blood, positive urine protein, rarely renal dysfunction, acute renal failure, interstitial nephritis.
2) Domestic post-marketing survey results
(1) As a result of a post-marketing use results survey conducted in Korea for 6 years, 338 adverse reactions were reported in 305 cases (5.40%) out of a total of 5,648 cases, regardless of causal relationship with the drug. Indigestion was the most common with 155 cases (2.74%), followed by facial edema in 54 cases (0.96%), abdominal pain in 33 cases (0.58%), nausea in 13 cases (0.23%), peripheral edema and rash in 12 cases each (0.21%), diarrhea in 10 cases (0.18%), and insomnia in 7 cases (0.12%).
(2) As other adverse reactions, headache and dizziness were reported in 5 cases each (0.09%), constipation, stomach ulcers, urticaria, and anemia were reported in 2 cases each (0.04%), and dry mouth, ulcerative stomatitis, gastritis, allergy, back pain, chest pain, hyperlipidemia, diabetes, weight gain, fracture, joint pain, RA factor positivity, shingles, pneumonia, difficulty breathing, elevation of ALT, and hearing loss were reported. 1 case (0.02%) was reported.
3) Overseas post-marketing survey results
Adverse reactions identified in post-marketing experience are as follows. Although these adverse reactions were confirmed in post-marketing reports, clinical trial data were referenced to assess frequency. As above, the incidence is based on the combined results of clinical trials representing exposure in 38,102 patients.
Definition of frequency: very common (≥ 10%), common (≥ 1%, < 10%), uncommon (≥ 0.1%, < 1%), rare (≥ 0.01%, < 0.1%), very rare (< 0.01%), frequency unknown (cannot be evaluated based on existing data)
(1) Immune system: very rare - anaphylactic reaction
(2) Mental world: rarely - hallucinations
(3) Nervous system: Very rare – cerebral hemorrhage, aseptic meningitis, loss of taste, loss of smell.
(4) Eyes: Uncommon - Conjunctivitis
(5) Blood vessels: very rare - vasculitis
(6) Respiration, chest and mediastinum: Rare - pulmonary embolism, interstitial pneumonia.
(7) Gastrointestinal tract: Rare - gastrointestinal bleeding.
(8) Hepatobiliary: rarely - hepatitis
Very rare - liver failure, fulminant hepatitis, liver necrosis, cholestasis, cholestatic hepatitis, jaundice.
(9) Skin and subcutaneous tissue: Rare - photosensitivity reaction.
Very rare - Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), exfoliative dermatitis.
(10) Renal and urinary system: Rare - acute renal failure, hyponatremia.
Very rare - tubulointerstitial nephritis, nephrotic syndrome, microlesion glomerulonephritis (11) Reproductive system and breast: rare - menstrual disorders
Frequency unknown† - Female infertility (reduced female fertility)
(12) Systemic body and administration site: Uncommon - chest pain
†Women planning pregnancy were excluded from all clinical trials, so it is not appropriate to refer to clinical trial data for the frequency of this adverse reaction.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. As the dose and exposure period of this drug increase, the cardiovascular risk increases, so administer it at the lowest effective dose for the shortest possible period. In particular, patients with osteoarthritis (degenerative arthritis) should be re-evaluated periodically.
2) Gastrointestinal effects: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, concurrent use of nonsteroidal anti-inflammatory drugs or aspirin, alcohol consumption, cardiovascular disease, smoking, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
3) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. Because inhibition of prostaglandin synthesis may cause deterioration of renal function and fluid retention, this drug should be administered with caution in patients with a history of heart failure, left ventricular dysfunction, or hypertension, or in patients with edema or fluid retention. Additionally, patients taking diuretics or at risk of hypovolemia for other reasons should also exercise caution when administering this drug.
5) Effects on kidneys: Non-steroidal anti-inflammatory drugs, including this drug, may cause nephrotoxicity. The renal effects of this drug in clinical trials were similar to those observed with the nonsteroidal anti-inflammatory drugs used as reference drugs. Long-term use of non-steroidal anti-inflammatory drugs may cause renal papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients at greatest risk of nephrotoxicity, such as patients with renal dysfunction, heart failure, liver dysfunction, patients taking diuretics, ACE inhibitors, or angiotensin II antagonists, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Effects on the liver: Not studied in patients with severe hepatic impairment (Child-Pugh Class C). Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal or required liver transplantation) were rarely reported with the administration of non-steroidal anti-inflammatory drugs, including this drug. For patients with symptoms and/or signs suggestive of liver function abnormality or for patients with abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration of this drug should be discontinued.
8) If symptoms or signs of anemia or blood loss appear due to long-term administration of this drug, a hemoglobin level or hematocrit level test should be performed. This drug generally does not affect platelet counts, prothrombin time (PT), or partial thromboplastin time (PTT), and does not inhibit platelet aggregation at recommended doses.
9) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, administration of this drug should be discontinued.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
11) Skin reaction: This drug is a sulfonamide class drug, and can cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms and may occur even in patients without a history of sulfa drug allergy. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and signs and should discontinue drug administration at the first symptoms and signs of hypersensitivity reactions such as skin rash, mucosal lesions or blisters, fever, and itching.
12) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
13) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
14) Due to the pharmacological properties of this drug, it may suppress fever and other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
15) For patients showing symptoms of severe dehydration, administer medication after providing fluids and observe carefully.
16) For acute pain relief in adults (pain relief after surgery or tooth extraction), it is used for a short period of time (within 1 week).
17) Two large-scale controlled clinical trials in which COX-2-selective non-steroidal anti-inflammatory drugs were administered to treat pain in the first 10 to 14 days immediately after coronary artery bypass grafting (CABG) showed an increase in the incidence of myocardial infarction and stroke.
18) Clinical tests (urinalysis, blood tests, kidney function tests, liver function tests, electrocardiograms, fecal occult blood tests, etc.) should be conducted on a regular or as needed basis, and if abnormalities are found, appropriate measures such as withdrawal of medication or discontinuation of administration should be taken.
19) Patients who experience dizziness or drowsiness after taking this drug should avoid driving or operating machinery.
20) This drug has no effect on platelet function, so it cannot be a substitute for acetylsalicylic acid for the prevention of cardiovascular thromboembolic disease. Because this drug does not inhibit platelet aggregation, patients receiving antiplatelet therapy (e.g., acetylsalicylic acid) should not discontinue treatment.
21) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
22) Cross-sensitivity: Patients who are sensitive to one NSAID may also be sensitive to other NSAIDs.
23) Patients with autoimmune diseases (e.g., patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)) may have an increased risk of developing aseptic meningitis when taking this drug.
24) Hyperkalemia may occur when this drug is administered to diabetic patients or in combination with drugs that increase blood potassium levels, so regular monitoring of potassium levels is necessary in these cases.
25) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
6. Interaction
1) This drug is mainly metabolized by CYP 2C9 in the liver, so caution should be exercised when co-administered with drugs that inhibit CYP 2C9. In patients suspected to be poor metabolizers of CYP 2C9 based on previous history or experience with other CYP 2C9 substrates, caution should be exercised when administering this drug as plasma concentrations may increase abnormally due to decreased clearance. Consider starting treatment at half the lowest recommended dose.
Co-administration of this drug with CYP 2C9 inhibitors may increase the plasma concentration of this drug. Therefore, when this drug is co-administered with a CYP 2C9 inhibitor, a dose reduction may be necessary.
Co-administration of this drug with CYP 2C9 inducers such as rifampicin, carbamazepine, and barbiturates may decrease the plasma concentration of this drug. Therefore, when this drug is co-administered with a CYP 2C9 inducer, an increase in the dose of this drug may be necessary.
2) Fluconazole and Ketoconazole: When fluconazole 200 mg is co-administered once a day, the metabolism of this drug through CYP 2C9 is inhibited by fluconazole, which doubles the blood concentration of this drug. Therefore, when starting concurrent use of this drug, administer at half the recommended dose.
Ketoconazole, a CYP 3A4 inhibitor, did not show clinically significant inhibition of the metabolism of this drug.
3) CYP 2D6: According to pharmacokinetic clinical studies and in vitro studies, this drug was found to be an inhibitor but not a substrate of CYP 2D6, so it may interact in vivo with drugs metabolized by CYP 2D6. When administered together with this drug, blood levels of antidepressants (tricyclics and SSRIs), neuroleptics, antiarrhythmic drugs, and dextromethorphan, which are CYP 2D6 substrates, may increase. When starting concomitant administration of this drug, a dose reduction of these drugs may be necessary, and when concomitant administration of this drug is discontinued, a dose increase of these drugs may be necessary.
4) In vitro studies confirmed that this drug partially inhibits metabolism mediated by CYP 2C19. The clinical significance of these results is unknown, but drugs metabolized by CYP 2C19 include diazepam, citalopram, and imipramine.
5) Antihypertensive drugs, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (also known as angiotensin receptor blockers, ARBs), diuretics, and beta-blockers: Inhibition of prostaglandins may reduce the effectiveness of antihypertensive drugs, including ACEIs, ARBs, diuretics, and beta-blockers. Caution should be exercised regarding this interaction when coadministering beta-blockers. When NSAIDs, including selective COX-2 inhibitors (celecoxib), are coadministered with ACE inhibitors, angiotensin II receptor antagonists, or diuretics to volume-depleted patients, including those with reduced renal function, the elderly, or those taking diuretics, it may lead to decreased renal function, including acute renal failure. Therefore, caution should be exercised when administering this combination, especially to the elderly. Patients should be adequately hydrated, and renal function should be monitored regularly after starting this combination treatment.
Lisinopril Study Results: In a 28-day controlled clinical trial of lisinopril in patients with hypertension stage I and II, co-administration of 200 mg twice daily (BID) did not result in a clinically significant increase in mean daily systolic or diastolic blood pressure as measured by 24-hour ambulatory blood pressure monitoring compared with placebo. Among patients co-administered with 200 mg BID, 48% had no response to lisinopril (defined as diastolic blood pressure > 90 mmHg or > 10% increase in diastolic blood pressure compared to baseline) at the final clinical visit, compared to 27% of patients co-administered with placebo. This was a statistically significant difference.
6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
7) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of NSAIDs. It can be administered in combination with low-dose aspirin (less than 325 mg per day), but it has been reported that the incidence of gastrointestinal adverse reactions (gastrointestinal ulcers) or other gastrointestinal complications is higher than when this drug is administered alone. When aspirin is administered as preventive therapy for the cardiovascular system, this drug does not have an effect on platelets and therefore cannot be used as a substitute for aspirin.
8) Dextromethorphan and metoprolol: When 200 mg of this drug was administered twice a day, the plasma concentrations of dextromethorphan and metoprolol (CYP 2D6 substrates) increased by 2.6-fold and 1.5-fold, respectively. This increase is due to the drug's inhibition of CYP 2D6 substrate metabolism through CYP 2D6. Therefore, when starting treatment with this drug, it may be necessary to reduce the dosage of drugs that are CYP 2D6 substrates, or when stopping treatment with this drug, the dosage of drugs that are CYP 2D6 substrates may need to be increased.
9) Lithium: When this drug and lithium are co-administered in healthy adults, the serum lithium concentration increases by about 17% and the renal clearance of lithium may decrease due to inhibition of prostaglandin synthesis in the kidney. Therefore, patients receiving lithium should be carefully observed for signs of lithium toxicity when starting or stopping treatment with this drug.
10) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered concurrently with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate. When celecoxib was administered in combination with methotrexate (rheumatoid treatment dose) to patients with rheumatoid arthritis, there was no significant effect. However, if the two drugs are coadministered, appropriate monitoring for methotrexate-related toxicity should be considered.
11) Oral anticoagulants: When NSAIDs and oral anticoagulants are administered together, the risk of bleeding may increase, so they should be administered with caution. Oral anticoagulants include warfarin/coumarins and newer anticoagulants (e.g., apixaban, dabigatran, rivaroxaban). For gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
In a study in which 2-5 mg of warfarin per day was administered to healthy subjects to determine the effect of this drug on the anticoagulant activity of warfarin, there was no effect on the anticoagulant activity as measured by prothrombin time. However, post-marketing studies have shown that serious bleeding associated with prolongation of the prothrombin time, which may be fatal, has been reported in patients receiving this drug in combination with warfarin, especially in the elderly.
Prolongation of prothrombin time (INR) has been reported; therefore, anticoagulation/INR should be monitored after starting or changing the dose in patients taking warfarin/coumarin anticoagulants.
12) Cyclosporine: Since the nephrotoxicity of cyclosporine or tacrolimus may increase due to co-administration of non-steroidal anti-inflammatory drugs and cyclosporine or tacrolimus, renal function should be monitored when co-administered with these drugs.
13) When this drug was taken with a high-fat meal, the peak plasma concentration was delayed by about 1-2 hours, and the total absorption (AUC) increased by 10-20%.
14) When this drug was administered in combination with antacids containing aluminum or magnesium, there was a 37% decrease in peak blood concentration and a 10% decrease in total absorption.
15) In addition to low-dose aspirin (less than 325 mg per day), co-administration with other non-steroidal anti-inflammatory drugs should not be performed as the risk of adverse reactions may increase.
16) Corticosteroids: There is a risk of increased gastrointestinal side effects (e.g. ulcers, bleeding). There is a particular risk for elderly people (over 65 years of age).
17) Oral contraceptives: In an interaction study, this drug did not have a clinically significant effect on the pharmacokinetics of a combined oral contraceptive (norethindrone 1 mg/ethinyl estradiol 0.035 mg).
18) When used together with fluvastatin, the blood concentration of this drug and fluvastatin may increase.
19) Other drugs: No clinically significant interactions were observed when this drug was co-administered with omeprazole, glibenclamide (glyburide), phenytoin, and tolbutamide.
7. Administration to pregnant and lactating women
1) In experiments on rats, it was reported that this drug does not delay parturition. However, the effect of this drug on labor and delivery in pregnant women is not known.
2) In a rabbit embryo/fetal development test, the rate of fetal abnormalities such as rib fusion and sternal segment fusion and the incidence of ventricular septal defects rarely increased when administered orally at doses above 150 mg/kg/day (about twice the AUC0-24 when administered to humans at 200 mg twice a day). In a rat embryo/fetal development study, a dose-dependent increase in diaphragmatic hernia was observed in fetuses when administered orally at a dose of 30 mg/kg/day or more (equivalent to approximately 6 times the AUC0-24 when administered to humans at 200 mg twice a day) in one of the two tests. In addition, when administered to rats in doses exceeding 50 mg/kg/day (a dose equivalent to approximately 6 times the AUC0-24 when administered to humans at 200 mg twice a day), it caused pre-implantation loss, post-implantation loss, and decreased fetal survival rate. Such toxicity was not observed in pregnancy 2 weeks after discontinuation of drug administration.
3) There is no clinical data on administering this drug to pregnant women. In animal experiments (rabbits and rats), administration of this drug has shown reproductive toxicity, including teratogenicity, but the potential risk to human pregnancy is unknown. Also, like other drugs that inhibit prostaglandin synthesis, this drug may cause uterine atony or premature closure of the fetal ductus arteriosus when administered late in pregnancy, so this drug should not be administered to pregnant women or women who may become pregnant. If pregnancy is confirmed while taking this drug, administration of this drug should be discontinued. This medicine is used in pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
4) The use of non-steroidal anti-inflammatory drugs, including this drug, may interfere with or delay follicular rupture due to their mechanism of action, which may cause reversible infertility in some women. Therefore, women who have difficulty conceiving or are undergoing infertility tests should consider discontinuing the use of non-steroidal anti-inflammatory drugs, including this drug.
5) Inhibition of prostaglandin synthesis may have an adverse effect on pregnancy. Epidemiological studies have shown that the risk of spontaneous miscarriage increases after taking drugs that inhibit prostaglandin synthesis in early pregnancy. Animal tests showed that implantation failure increased when drugs that inhibit prostaglandin synthesis were administered.
6) Administration of non-steroidal anti-inflammatory drugs during the second or third trimester of pregnancy may cause abnormalities in fetal kidney function, which may lead to a decrease in the amount of amniotic fluid or oligohydramnios in severe cases. These effects may appear immediately after starting drug administration and are generally reversible. Amniotic fluid volume should be closely monitored in pregnant women taking this drug.
7) This drug is excreted in rat breast milk at a concentration similar to that in plasma. Based on limited data from one subject, it is believed that this drug may also pass into human breast milk. Many drugs not only pass into breast milk, but if they do so, there is concern that serious adverse reactions may occur in infants. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.
8. Administration to children
Safety and effectiveness in children and adolescents under 18 years of age have not been established.
9. Administration to elderly people
1) Elderly people are more likely to have decreased renal function, liver function, and especially cardiac function, so appropriate observation is required when administering this drug to the elderly.
2) According to clinical trials, there was no significant difference in effectiveness between elderly and young subjects. In clinical trials comparing kidney function (GFR, BUN, creatinine) and platelet function (bleeding time, degree of platelet aggregation), there were no differences between older and younger subjects. However, as with other NSAIDs, including selective COX-2 inhibitors, spontaneous post-marketing adverse reactions of fatal gastrointestinal adverse events and acute renal dysfunction were more frequently reported in elderly patients.
3) In general, dosage adjustment is not required for the elderly, but if the body weight is less than 50 kg, administration should be started at the lowest dose.
10. Effect on clinical test values
1) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should regularly undergo complete blood count (CBC) and physicochemical tests. If abnormal liver function test results or renal function test results persist or worsen, treatment with this drug should be discontinued.
2) As with other non-steroidal anti-inflammatory drugs, BUN elevations were observed more frequently than placebo in clinical trials, but clinical significance was not confirmed.
11. Treatment in case of overdose
1) Overdose of this drug has not been reported during clinical trials. No serious toxicity occurred in 12 patients when administered at doses up to 2,400 mg/day for up to 10 days.
2) Symptoms of overdosage of non-steroidal anti-inflammatory drugs generally include lethargy, drowsiness, nausea, vomiting, and upper abdominal pain, and can be recovered with auxiliary treatment. Gastrointestinal bleeding may also occur, and in rare cases, hypertension, acute renal failure, respiratory depression, and coma may occur.
3) Symptomatic and supportive treatment is usually performed, and there is no specific antidote.
4) If symptoms appear within 4 hours of taking the drug or if a very large dose is taken, vomiting, activated charcoal (60-100 g per kg for adults, 1-2 g per kg for children), and osmotic diarrhea can be used.
5) Treatments such as hemodialysis, forced diuresis, urinary alkalinization, and blood perfusion are not useful due to the high protein binding rate of celecoxib.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 2items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 2 | Seleca Tab. 200mg | Selekka tablet 200 mg (precautions for use) | 2018.01.05 | HWPCelecoxib single oral medication unification adjustment plan.hwp |
| 1 | Seleca Tab. 200mg | Selekka Tablet 200 mg (Precautions for use) | 2016.06.28 | HWPCelecoxib single oral medication unification adjustment plan.hwp |